सनोफी इंडिया शेअर किंमत

Pharmaceuticals company Sanofi India announced Q1CY26 & CY25 results Q1CY26 Financial Highlights: Revenue from Operations: Rs 4,723 million in Q1CY26, compared to Rs 4,198 million in Q4CY25 (up 12.51% QoQ) and Rs 5,359 million in Q1CY25 (down 11.87% YoY). Total Income: Rs 4,767 million in Q1CY26, compared to Rs 4,226 million in Q4CY25 (up 12.80% QoQ) and Rs 5,392 million in Q1CY25 (down 11.59% YoY). Profit for the period: Rs 1,026 million in Q1CY26, compared to Rs 617 million in Q4CY25 (up 66.29% QoQ) and Rs 1,195 million in Q1CY25 (down 14.14% YoY). Total Comprehensive Income: Rs 1,026 million in Q1CY26, compared to Rs 634 million in Q4CY25 (up 61.83% QoQ) and Rs 1,195 million in Q1CY25 (down 14.14% YoY). Basic and Diluted EPS: Rs 44.55 in Q1CY26, compared to Rs 26.79 in Q4CY25 (up 66.29% QoQ) and Rs 51.89 in Q1CY25 (down 14.14% YoY). CY25 Financial Highlights: Revenue from Operations: Rs 18,374 million. Total Income: Rs 18,571 million. Profit for the year: Rs 3,267 million. Total Comprehensive Income: Rs 3,284 million. Basic and Diluted EPS: Rs 141.85. Business Highlights: Insulin Portfolio: The domestic insulin portfolio achieved 14% growth compared to the previous quarter and 19% growth compared to the previous year, demonstrating strong equity in the Diabetes Injectable segment. Strategic Partnerships: The company continues to build foundations through strategic partnerships in Cardiovascular (CV), Oral anti Diabetes (OAD), and Central Nervous System (CNS) segments. Impact of Transitions: Overall results for the quarter were impacted by transactions relating to partnership transitions. Export Sales: Export sales are stabilizing despite the ongoing geopolitical situation. Operational Excellence: The company is driving efficiency improvements through targeted market initiatives, refined go-to-market strategies, and operational excellence programs. Board Changes: Mr. Rahul Bhatnagar has been appointed as the Chairman of the Board effective April 30, 2026, following the completion of tenure of Mr. Aditya Narayan and Mrs. Usha Thorat. Deepak Arora, Managing director, said: "Despite current focus on newer diabetes therapies, our 14% registered growth (vs previous quarter) and 19% registered growth (vs last year) validates what clinical guidelines consistently affirm: insulin remains essential for comprehensive diabetes care. Our success across both public and private sectors reflects the medical community's continued trust in insulin as the gold standard for reliable, predictable diabetes management — a position that remains unshakeable regardless of market trends. Our strategic partnerships will catalyse growth, strengthen our commercial footprint, enhance market penetration, and create meaningful connections with healthcare professionals across therapeutic areas. We remain committed to driving operational excellence while broadening access to both established and innovative therapies, throughout India." Result PDF

• ट्रेंडलाईन
• 3 आठवडे 2 दिवसांपूर्वी

Pharmaceuticals company Sanofi India announced Q4CY25 results Revenue from operations: Rs 4,198 million against Rs 5,149 million during Q4CY24, change -18%. PBT: Rs 830 million against Rs 1,222 million during Q4CY24, change -32%. PAT: Rs 617 million against Rs 913 million during Q4CY24, change -32%. EPS: Rs 26.79 for Q4CY25. Result PDF

• ट्रेंडलाईन
• 2 महिने 3 आठवड्यांपूर्वी

Conference Call with Sanofi India Management and Analysts on Q3CY25 Performance and Outlook. Listen to the full earnings transcript.

• ट्रेंडलाईन
• 6 महिने 3 आठवड्यांपूर्वी